Adipositas und metabolisches Syndrom

M. Blüher; A. Hamann

doi:10.1055/s-0033-1335720

Diabetologie und Stoffwechsel, Table of Contents

Diabetologie und Stoffwechsel 2013; 8(3): 31-46
DOI: 10.1055/s-0033-1335720

DuS-Refresher

Adipositas und metabolisches Syndrom

Authors

M. Blüher

¹Klinik für Endokrinologie, Universität Leipzig
A. Hamann

²Medizinische Klinik IV, Hochtaunus-Kliniken, Bad Homburg

Abstract

Full Text

References

Literatur
1 Hauner H, Buchholz G, Hamann A et al. Evidenzbasierte Leitlinie – Prävention und Therapie der Adipositas. Deutsche Adipositas-Gesellschaft, Deutsche Diabetes-Gesellschaft, Deutsche Gesellschaft für Ernährung, Deutsche Gesellschaft für Ernährungsmedizin (Hrsg.). 2007 www.adipositas-gesellschaft.de
2 Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428
3 Blüher M, Stumvoll M. Metabolic syndrome – myths, mechanisms, management. Dtsch Med Wochenschr 2006; 131: 1167-1172
4 Hanefeld M, Leonhardt W. Das metabolische Syndrom. Dt Gesundheitswesen 1981; 36: 545-551
5 Mensink GB, Lampert T, Bergmann E. Übergewicht und Adipositas in Deutschland 1984-2003. Bundesgesundheitsblatt Gesundheitsforschung. Gesundheitsschutz 2005; 48: 1348-1356
6 Hauner H, Bramlage P, Lösch C et al. Prevalence of obesity in primary care using different anthropometric measures--results of the German Metabolic and Cardiovascular Risk Project (GEMCAS). BMC Public Health 2008; 8: 282
7 Wirth A, Hauner H. Das Metabolische Syndrom. München: Urban & Vogel; 2007
8 Grundy SM, Cleeman JI, Daniels SR. . American Heart Association; National Heart, Lung, and Blood Institute. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752
9 Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 2002; 105: 310-315
10 Hebebrand J, Friedel S, Schäuble N et al. Perspectives: molecular genetic research in human obesity. Obes Rev 2003; 4: 139-146
11 Frayling TM, Timpson NJ, Weedon MN et al. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007; 316 (11) 889-894
12 Church C, Moir L, McMurray F et al. Overexpression of Fto leads to increased food intake and results in obesity. Nat Genet 2010; 42 (12) 1086-1092
13 Shen BJ, Todaro JF, Niaura R et al. Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 2003; 157: 701-711
14 Klöting N, Stumvoll M, Blüher M. The biology of visceral fat. Internist 2007; 48: 126-133
15 Engeli S. Role of the renin-angiotensin-aldosterone system in the metabolic syndrome. Contrib Nephrol 2006; 151: 122-134
16 Tuomilehto J, Lindstrom J, Eriksson J et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-1350
17 Esposito K, Marfella R, Ciotola M et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 2004; 92: 1440-1446
18 Shai I, Schwarzfuchs D, Henkin Y et al. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. N Engl J Med 2008; 359: 229-241
19 Hamann A. Pharmakotherapie der Adipositas. Internist 2008; (im Druck)
20 Schindler C, Chavakis T, Lamounier-Zepter V et al. Pharmacological concepts for the treatment of obesity – a therapeutic meander?. Dtsch Med Wochenschr 2011; 136 (31) 1570-1573
21 Hamann A, Morcos M, Nawroth P. Diabetes mellitus Typ 2 – Medikamentöse Therapie. CME 2006; 3: 11-20
22 UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
23 Nauck MA. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011; 124 (Suppl. 01) S3-S18
24 Clar C, Gill JA, Court R et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open 2012; 2 (05)
25 Bosch J, Yusuf S, Gerstein HC et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-1562
26 Sjöström L, Narbro K, Sjöström CD et al. Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752
27 Fachkommission Diabetes in Sachsen. Praxisleitlinie Metabolisch-Vaskuläres Syndrom. Dresden: 2006 www.imib.med.tu-dresden.de/diabetes
28 Zimmet P, Alberti KG. Surgery or medical therapy for obese patients with type 2 diabetes?. N Engl J Med 2012; 366 (17) 1635-1636